tradingkey.logo

Nexalin Technology Inc

NXL
0.515USD
-0.105-16.95%
종가 02/06, 16:00ET시세는 15분 지연됩니다
9.37M시가총액
손실P/E TTM

Nexalin Technology Inc

0.515
-0.105-16.95%

자세한 내용은 Nexalin Technology Inc 회사

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc 정보

종목 코드 NXL
회사 이름Nexalin Technology Inc
상장일Sep 16, 2022
CEOWhite (Mark)
직원 수6
유형Ordinary Share
회계 연도 종료Sep 16
주소1776 Yorktown
도시HOUSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호77056
전화18322600222
웹사이트https://nexalin.com
종목 코드 NXL
상장일Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%

수익 분석

통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
지역별USD
이름
수익
비율
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
사업별
지역별
사업별USD
이름
수익
비율
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

주식 보유 통계

마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
기타
86.14%
주주
주주
비율
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
기타
86.14%
주주 유형
주주
비율
Individual Investor
13.78%
Investment Advisor
1.59%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
기타
82.35%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
38
722.74K
3.87%
-783.30K
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Elson (Marilyn)
1.54M
8.23%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.02%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.66%
--
--
Jun 04, 2025
Owens (David)
185.75K
1%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
176.58K
0.95%
+16.70K
+10.45%
Sep 30, 2025
MYDA Advisors LLC
150.00K
0.8%
-650.00K
-81.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
121.82K
0.65%
+5.45K
+4.69%
Sep 30, 2025
Kazden (Alan)
83.13K
0.45%
--
--
Jun 04, 2025
Susquehanna International Group, LLP
62.50K
0.34%
+62.50K
--
Sep 30, 2025
Renaissance Technologies LLC
55.70K
0.3%
+9.36K
+20.19%
Sep 30, 2025
더 보기

관련 ETF

이름
비율
데이터 없음

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
KeyAI